These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

623 related articles for article (PubMed ID: 16716095)

  • 1. Premature cardiovascular disease in young women with heterozygous familial hypercholesterolemia.
    van der Graaf A; Hutten BA; Kastelein JJ; Vissers MN
    Expert Rev Cardiovasc Ther; 2006 May; 4(3):345-51. PubMed ID: 16716095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Familial hypercholesterolemia: current treatment and advances in management.
    Huijgen R; Vissers MN; Defesche JC; Lansberg PJ; Kastelein JJ; Hutten BA
    Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):567-81. PubMed ID: 18402545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma lipoprotein(a) levels and LDL-cholesterol lowering response to statin therapy in patients with heterozygous familial hypercholesterolemia.
    Miltiadous G; Saougos V; Cariolou M; Elisaf MS
    Ann Clin Lab Sci; 2006; 36(3):353-5. PubMed ID: 16951279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades.
    Elis A; Zhou R; Stein EA
    Am J Cardiol; 2011 Jul; 108(2):223-6. PubMed ID: 21545982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Is statin treatment for children safe and effective?].
    Marchetti F; Cannioto Z
    Recenti Prog Med; 2008 Dec; 99(12):599-601. PubMed ID: 19388217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there a problem with ezetimibe or just ENHANCEd hype?
    Whayne TF
    Angiology; 2008 Dec-2009 Jan; 59(6):661-3. PubMed ID: 18796445
    [No Abstract]   [Full Text] [Related]  

  • 7. In brief: Zetia and Vytorin: the ENHANCE study.
    Med Lett Drugs Ther; 2008 Jan; 50(1278):5. PubMed ID: 18219263
    [No Abstract]   [Full Text] [Related]  

  • 8. Heterozygous familial hypercholesterolemia case study.
    Friedrich DA
    J Am Acad Nurse Pract; 2010 Oct; 22(10):523-6. PubMed ID: 21040085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
    Pappu AS; Bacon SP; Illingworth DR
    J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventing early cardiovascular death in patients with familial hypercholesterolemia.
    Repas TB; Tanner JR
    J Am Osteopath Assoc; 2014 Feb; 114(2):99-108. PubMed ID: 24481802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TaqIB polymorphism in CETP gene: the influence on incidence of cardiovascular disease in statin-treated patients with familial hypercholesterolemia.
    Mohrschladt MF; van der Sman-de Beer F; Hofman MK; van der Krabben M; Westendorp RG; Smelt AH
    Eur J Hum Genet; 2005 Jul; 13(7):877-82. PubMed ID: 15856070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe xanthomatosis in heterozygous familial hypercholesterolemia.
    Aljenedil S; Ruel I; Watters K; Genest J
    J Clin Lipidol; 2018; 12(4):872-877. PubMed ID: 29778561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia.
    Clauss SB; Holmes KW; Hopkins P; Stein E; Cho M; Tate A; Johnson-Levonas AO; Kwiterovich PO
    Pediatrics; 2005 Sep; 116(3):682-8. PubMed ID: 16140708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [LDL cholesterol--why lower and lower?].
    Müller-Wieland D; Kotzka J
    MMW Fortschr Med; 2007 May; 149(22):28-30. PubMed ID: 18069223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ["The lower LDL cholesterol levels, the better" still valid. Negative/neutral conclusions of three studies on statins do not change the clinical practice].
    Olsson AG; Nilsson PM
    Lakartidningen; 2009 Mar 18-24; 106(12):854-7. PubMed ID: 19452786
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands.
    Pijlman AH; Huijgen R; Verhagen SN; Imholz BP; Liem AH; Kastelein JJ; Abbink EJ; Stalenhoef AF; Visseren FL
    Atherosclerosis; 2010 Mar; 209(1):189-94. PubMed ID: 19818960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy.
    Raal FJ; Pilcher GJ; Panz VR; van Deventer HE; Brice BC; Blom DJ; Marais AD
    Circulation; 2011 Nov; 124(20):2202-7. PubMed ID: 21986285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. After the failure of ENHANCEd cholesterol lowering in familial hypercholesterolemia, SEAS of problems with ezetimibe.
    Mascitelli L; Ravnskov U; Pezzetta F; Goldstein MR
    Angiology; 2009; 60(1):127-8; author reply 129-30. PubMed ID: 19049996
    [No Abstract]   [Full Text] [Related]  

  • 19. New treatments on the horizon for familial hypercholesterolemia.
    Allian-Sauer MU; Falko JM
    Expert Rev Cardiovasc Ther; 2012 Oct; 10(10):1227-37. PubMed ID: 23190063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebral cholesterol granuloma in homozygous familial hypercholesterolemia.
    Francis GA; Johnson RL; Findlay JM; Wang J; Hegele RA
    CMAJ; 2005 Feb; 172(4):495-7. PubMed ID: 15710941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.